The Cancer Prevention and Control Research Program (CPC) of the YCC was initiated in the mid-1980s,with the selection of Yale as one of the first two NIH-funded Cancer Prevention Research Units (CPRUs) inthe United States (US). In 1993, Dr. Susan Mayne was appointed as Program Leader, and in 1995, she wasappointed as Associate Director for Population Science of the Center. Dr. Mayne oversees all aspects ofprevention and control research for the YCC. CPC has a long and rich history of using the State ofConnecticut as a population laboratory for cancer prevention and control research. The program is enhancedby its link to the Connecticut Tumor Registry, the oldest population-based tumor registry in the US and anNCI-funded SEER (Surveillance, Epidemiology, and End Results Program) site. In addition, researchershave access to the YCC Rapid Case Ascertainment Shared Resource (RCA), which identifies patients withnewly diagnosed cancer throughout the State on a rapid basis, facilitating research projects. This SharedResource is unique, and is complemented by the Molecular Epidemiology Shared Resource, allowing forpopulation-based molecular epidemiology research. The program can thematically be grouped into twoprimary themes. The first theme is lifestyle factors and genetics in the etiology of cancer, with the objective ofelucidating the roles of (a) nutrition, physical activity, and obesity in cancer; (b) environmental factors andcancer; and (c) molecular/genetic factors in cancer in human populations. The program also evaluates thecauses of and approaches for mitigation of (d) racial disparities and cancer; and (e) develops new statisticalmethodologies to inform researchers in the areas above. The second major theme is behavioralinterventions in cancer prevention/control. Research emphasizes the use of behavioral interventions topromote effective cancer prevention and control interventions, ranging from primary prevention (tobaccocontrol, diet change) through early detection message framing, to survivorship interventions and finally toend-of-life care. The program has a total of 29 program members representing 4 schools and 9 departments.Program members have a total of $6.7 million in research grant funding (annual direct costs), of which $6.1million direct costs is peer-reviewed. Of this, $1.8 million is NCI-funded. Program members contributed atotal of 360 publications since the last renewal, of which 33% percentage are intra-programmatic and 8.3%percentage are interprogrammatic. Program members collaborate with other relevant groups at Yaleincluding the Transdisciplinary Tobacco Use Research Center and the YCC Cancer Information Service, andthe Program is the host for several training programs including an NCI-funded pre-doctoral training programin cancer epidemiology and genetics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016359-29
Application #
7513247
Study Section
Subcommittee G - Education (NCI)
Project Start
2007-08-09
Project End
2012-07-31
Budget Start
2007-08-09
Budget End
2008-07-31
Support Year
29
Fiscal Year
2007
Total Cost
$17,138
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331

Showing the most recent 10 out of 675 publications